Oruka Therapeutics SVP Agarwal sells over $926k in common stock

Chief Operating Officer Laura Lee Sandler of Oruka Therapeutics, Inc. (NASDAQ: ORKA) recently sold 906 shares of the company's common stock on September 15, 2026. The total value of these shares was $86,713, with each share priced at $95.71. The transactions were executed under Oruka Therapeutics' automatic sell-to-cover procedure, designed to meet tax withholding requirements related to the vesting of restricted stock units.

Following the sale, Sandler still holds 235,478 shares of Oruka Therapeutics common stock. Currently, ORKA stock has risen by 519% over the past year, trading at $92.20 with a market capitalization of $6.35 billion. Analysts, however, consider the stock overvalued, positioning it among companies on the Most Overvalued list. Despite the stock's performance, Oruka Therapeutics remains unprofitable, with earnings per share at -$2.02.

The company continues to attract attention from analysts, with price targets ranging from $117 to $200. Oruka Therapeutics has also been the subject of strategic developments, including UBS raising its price target to $130 and H.C. Wainwright echoing this stance with a $120 target. Additionally, the company recently appointed Todd Edwards as its Chief Commercial Officer, bringing extensive experience in immunology and dermatology.